STATCenter·
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Read at STAT →
Health · 1 sources covering this
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/04115afd48ab29981e54ee1f51818134369bc7fa" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials"></iframe>
